You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Article metrics

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - other biologic treatment
SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

 

Online download statistics by month:

Online download statistics by month: June 2014 to March 2024

AbstractFullPdf
Jun 2014300
Jul 2014900
Aug 2014701
Sep 2014400
Oct 2014701
Nov 20141200
Dec 20141201
Jan 2015300
Feb 2015100
Mar 20152001
Apr 2015700
May 20152000
Jun 2015400
Jul 2015500
Aug 2015500
Sep 20151701
Oct 2015500
Nov 2015903
Dec 20151801
Jan 2016200
Feb 20161101
Mar 20161302
Apr 2016900
May 20161301
Jun 20161101
Jul 20162100
Aug 20161002
Sep 2016400
Oct 2016600
Nov 2016401
Dec 2016600
Jan 2017901
Feb 2017400
Mar 2017800
Apr 2017802
May 2017900
Jun 2017701
Jul 2017600
Aug 20171201
Sep 20171000
Oct 2017200
Nov 2017200
Dec 20171400
Jan 20181200
Feb 2018400
Mar 2018801
Apr 20181200
May 2018800
Jun 2018800
Jul 2018400
Aug 20181000
Sep 2018400
Oct 2018802
Nov 20181802
Dec 20181000
Jan 2019200
Mar 2019200
Apr 2019700
Jun 20191200
Jul 2019001
Sep 2019200
Feb 2020400
May 2020300
Jul 2020800
Aug 2020200
Sep 20201001
Oct 2020400
Nov 2020400
Dec 2020200
Jan 2021200
Feb 2021400
Apr 2021400
May 2021100
Oct 2021200
Nov 2021200
Dec 2021801
Jan 2022600
Feb 2022200
Mar 2022200
Apr 2022200
May 2022600
Jun 2022200
Jul 20221800
Aug 20221400
Sep 20221203
Oct 20221000
Nov 2022600
Dec 2022800
Feb 2023400
Mar 2023400
Apr 2023200
May 2023600
Jul 2023600
Aug 2023400
Sep 2023600
Dec 2023600
Jan 20241400
Mar 2024600
Total706033